The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court.
The agreement, announced in a statement from Arcturus, ostensibly brings an end to a power struggle for control of the fledgling biotech that pitted Payne against his own board of directors. No financial terms were disclosed. The fight spilled into the open earlier this year, when the board announced it had fired Payne, who is the largest Arcturus… Read more »
UNDERWRITERS AND PARTNERS